Estonia

Estonia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.53 (0.45 - 0.61) 2019 Modelled IHME
0.54 (0.46 - 0.62) 2018 Modelled IHME
0.55 (0.46 - 0.64) 2017 Modelled IHME
0.55 (0.47 - 0.64) 2016 Modelled IHME
0.56 (0.47 - 0.65) 2015 Modelled IHME
0.56 (0.49 - 0.64) 2014 Modelled IHME
0.57 (0.50 - 0.65) 2013 Modelled IHME
0.59 (0.51 - 0.67) 2012 Modelled IHME
0.6 (0.52 - 0.68) 2011 Modelled IHME
0.61 (0.52 - 0.70) 2010 Modelled IHME
0.62 (0.54 - 0.71) 2009 Modelled IHME
0.64 (0.55 - 0.72) 2008 Modelled IHME
0.65 (0.55 - 0.74) 2007 Modelled IHME
0.67 (0.56 - 0.76) 2006 Modelled IHME
0.68 (0.57 - 0.78) 2005 Modelled IHME
0.68 (0.58 - 0.79) 2004 Modelled IHME
0.69 (0.59 - 0.79) 2003 Modelled IHME
0.69 (0.59 - 0.80) 2002 Modelled IHME
0.7 (0.59 - 0.81) 2001 Modelled IHME
0.7 (0.60 - 0.82) 2000 Modelled IHME
0.71 (0.61 - 0.83) 1999 Modelled IHME
0.73 (0.62 - 0.84) 1998 Modelled IHME
0.74 (0.63 - 0.86) 1997 Modelled IHME
0.75 (0.64 - 0.87) 1996 Modelled IHME
0.75 (0.63 - 0.87) 1995 Modelled IHME
0.75 (0.63 - 0.86) 1994 Modelled IHME
0.75 (0.63 - 0.86) 1993 Modelled IHME
0.75 (0.62 - 0.86) 1992 Modelled IHME
0.74 (0.61 - 0.87) 1991 Modelled IHME
0.73 (0.59 - 0.87) 1990 Modelled IHME
0 (0 - 2) 2013 Survey/reported Parke, 2017
1.12 (0.18 - 7.92) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.03 (0.02 - 0.04) 2019 Modelled IHME
0.03 (0.02 - 0.04) 2018 Modelled IHME
0.03 (0.02 - 0.04) 2017 Modelled IHME
0.03 (0.02 - 0.04) 2016 Modelled IHME
0.03 (0.02 - 0.04) 2015 Modelled IHME
0.03 (0.02 - 0.04) 2014 Modelled IHME
0.03 (0.02 - 0.04) 2013 Modelled IHME
0.03 (0.02 - 0.04) 2012 Modelled IHME
0.03 (0.02 - 0.04) 2011 Modelled IHME
0.03 (0.02 - 0.04) 2010 Modelled IHME
0.03 (0.02 - 0.04) 2009 Modelled IHME
0.03 (0.02 - 0.04) 2008 Modelled IHME
0.04 (0.03 - 0.05) 2007 Modelled IHME
0.04 (0.03 - 0.05) 2006 Modelled IHME
0.05 (0.03 - 0.06) 2005 Modelled IHME
0.08 (0.06 - 0.11) 2004 Modelled IHME
0.14 (0.10 - 0.19) 2003 Modelled IHME
0.22 (0.16 - 0.30) 2002 Modelled IHME
0.3 (0.22 - 0.40) 2001 Modelled IHME
0.36 (0.26 - 0.48) 2000 Modelled IHME
0.41 (0.29 - 0.54) 1999 Modelled IHME
0.45 (0.32 - 0.60) 1998 Modelled IHME
0.49 (0.34 - 0.65) 1997 Modelled IHME
0.52 (0.36 - 0.69) 1996 Modelled IHME
0.53 (0.36 - 0.70) 1995 Modelled IHME
0.53 (0.37 - 0.69) 1994 Modelled IHME
0.52 (0.37 - 0.69) 1993 Modelled IHME
0.52 (0.36 - 0.69) 1992 Modelled IHME
0.51 (0.35 - 0.69) 1991 Modelled IHME
0.5 (0.34 - 0.69) 1990 Modelled IHME
0.36 (0.06 - 2.81) 2015 Modelled WHO
Showing out of
Show more
Men who have sex with men (MSM)
Download
Value (%) Year Type Source
1.03 (0 - 5.60) 2015 Survey/reported K. R. Tervise Arengu Instituut, 2015.

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
17 (12 - 23) 2019 Modelled IHME
17 (12 - 23) 2018 Modelled IHME
17 (12 - 24) 2017 Modelled IHME
17 (12 - 24) 2016 Modelled IHME
17 (12 - 24) 2015 Modelled IHME
17 (12 - 24) 2014 Modelled IHME
17 (12 - 24) 2013 Modelled IHME
18 (12 - 25) 2012 Modelled IHME
18 (13 - 25) 2011 Modelled IHME
18 (13 - 25) 2010 Modelled IHME
19 (13 - 26) 2009 Modelled IHME
19 (13 - 26) 2008 Modelled IHME
19 (14 - 27) 2007 Modelled IHME
20 (14 - 28) 2006 Modelled IHME
20 (14 - 28) 2005 Modelled IHME
21 (14 - 28) 2004 Modelled IHME
21 (15 - 29) 2003 Modelled IHME
22 (15 - 30) 2002 Modelled IHME
22 (16 - 31) 2001 Modelled IHME
22 (16 - 31) 2000 Modelled IHME
23 (16 - 31) 1999 Modelled IHME
23 (17 - 32) 1998 Modelled IHME
24 (17 - 32) 1997 Modelled IHME
24 (17 - 33) 1996 Modelled IHME
25 (18 - 33) 1995 Modelled IHME
25 (18 - 34) 1994 Modelled IHME
24 (18 - 33) 1993 Modelled IHME
24 (17 - 32) 1992 Modelled IHME
24 (17 - 32) 1991 Modelled IHME
24 (17 - 32) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
93 2018 Survey/reported WHO/UNICEF
92 2017 Survey/reported WHO/UNICEF
93 2016 Survey/reported WHO/UNICEF
91 2015 Survey/reported WHO/UNICEF
93 2014 Survey/reported WHO/UNICEF
93 2013 Survey/reported WHO/UNICEF
94 2012 Survey/reported WHO/UNICEF
94 2011 Survey/reported WHO/UNICEF
94 2010 Survey/reported WHO/UNICEF
95 2009 Survey/reported WHO/UNICEF
94 2008 Survey/reported WHO/UNICEF
95 2007 Survey/reported WHO/UNICEF
95 2006 Survey/reported WHO/UNICEF
95 2005 Survey/reported WHO/UNICEF
90 2004 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
232 2017 Survey/reported EMCDDA, 2019
249 (135 - 339) 2016 Survey/reported Estonia National Institute for Health Development, 2016.
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2003
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
2.05 (1.67 - 2.51) 2019 Modelled IHME
2.05 (1.69 - 2.51) 2018 Modelled IHME
2.04 (1.68 - 2.50) 2017 Modelled IHME
2.03 (1.67 - 2.47) 2016 Modelled IHME
2.01 (1.63 - 2.47) 2015 Modelled IHME
2.02 (1.65 - 2.46) 2014 Modelled IHME
2.03 (1.65 - 2.47) 2013 Modelled IHME
2.05 (1.67 - 2.48) 2012 Modelled IHME
2.06 (1.67 - 2.49) 2011 Modelled IHME
2.06 (1.67 - 2.50) 2010 Modelled IHME
2.06 (1.66 - 2.50) 2009 Modelled IHME
2.06 (1.67 - 2.50) 2008 Modelled IHME
2.05 (1.67 - 2.49) 2007 Modelled IHME
2.05 (1.66 - 2.48) 2006 Modelled IHME
2.04 (1.65 - 2.49) 2005 Modelled IHME
2.03 (1.65 - 2.47) 2004 Modelled IHME
2.02 (1.64 - 2.47) 2003 Modelled IHME
2 (1.63 - 2.44) 2002 Modelled IHME
1.98 (1.61 - 2.44) 2001 Modelled IHME
1.97 (1.59 - 2.43) 2000 Modelled IHME
1.95 (1.59 - 2.39) 1999 Modelled IHME
1.93 (1.58 - 2.37) 1998 Modelled IHME
1.91 (1.56 - 2.35) 1997 Modelled IHME
1.89 (1.54 - 2.33) 1996 Modelled IHME
1.87 (1.52 - 2.31) 1995 Modelled IHME
1.86 (1.51 - 2.29) 1994 Modelled IHME
1.85 (1.50 - 2.27) 1993 Modelled IHME
1.83 (1.49 - 2.26) 1992 Modelled IHME
1.82 (1.48 - 2.24) 1991 Modelled IHME
1.81 (1.45 - 2.25) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0 (0 - 2) 2013 Survey/reported Parker, 2018
Men who have sex with men (MSM)
Download
Value (%) Year Type Source
1.8 (0.20 - 6.20) 2015 Survey/reported K. R. Tervise Arengu Instituut, 201
People who inject drugs (PWID)
Download
Value (%) Year Type Source
79.2 (67.40 - 91) 2014 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
28 (20 - 36) 2019 Modelled IHME
27 (20 - 36) 2018 Modelled IHME
28 (20 - 36) 2017 Modelled IHME
27 (20 - 35) 2016 Modelled IHME
27 (19 - 35) 2015 Modelled IHME
27 (19 - 35) 2014 Modelled IHME
27 (19 - 35) 2013 Modelled IHME
27 (19 - 35) 2012 Modelled IHME
27 (19 - 35) 2011 Modelled IHME
27 (19 - 35) 2010 Modelled IHME
27 (19 - 35) 2009 Modelled IHME
26 (19 - 35) 2008 Modelled IHME
26 (19 - 35) 2007 Modelled IHME
27 (19 - 35) 2006 Modelled IHME
27 (19 - 35) 2005 Modelled IHME
27 (19 - 35) 2004 Modelled IHME
27 (19 - 36) 2003 Modelled IHME
27 (19 - 35) 2002 Modelled IHME
27 (19 - 36) 2001 Modelled IHME
27 (20 - 36) 2000 Modelled IHME
27 (20 - 36) 1999 Modelled IHME
27 (20 - 36) 1998 Modelled IHME
27 (20 - 36) 1997 Modelled IHME
28 (20 - 36) 1996 Modelled IHME
27 (19 - 35) 1995 Modelled IHME
27 (19 - 35) 1994 Modelled IHME
27 (20 - 36) 1993 Modelled IHME
28 (20 - 36) 1992 Modelled IHME
28 (20 - 36) 1991 Modelled IHME
28 (20 - 37) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 2017 Survey/reported EMCDDA, 2019
249 (135 - 339) 2016 Survey/reported Estonia National Institute for Health Development, 2016.
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2003
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.53 (%)
2019
(0.45 - 0.61(%))
IHME
HCV (RNA/cAg+)
2.05 (%)
2019
(1.67 - 2.51(%))
IHME

Survey/surveillance

HBV (HBsAg+)
0 (%)
2013
(0 - 2(%))
Parke, 2017
HCV (anti-HCV)
0 (%)
2013
(0 - 2(%))
Parker, 2018

Hepatitis related deaths (national)

Modelled

HBV
49
2019
(35 - 69)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
75
2019
(52 - 105)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.03 (%)
2019, latest modelled
(0.02 - 0.04(%))
IHME

Prevalence PWID

HCV
79.20 (%)
2014, latest modelled
(67.40 - 91(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
232
2017
EMCDDA, 2019
Eligible for HBV generic medicines
Eligible for HCV generic medicines